Drug intelligence / Profile preview

LBVE02

Development stage: Preclinical
Lead developer: LG Chem
Modality: Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration: Intramuscular

Overview

LBVE02 is a pneumococcal CRM197 protein conjugate vaccine developed as an immunostimulant. It is designed to induce immunity against *Streptococcus pneumoniae* by using the CRM197 protein as a carrier for pneumococcal polysaccharides, thereby enhancing the immune response. The vaccine was initially developed by LG Chem and has been evaluated in clinical settings for its efficacy in preventing pneumococcal infections[1][4].

Other names: LBVE-02LBVE02LBVE 02

Targets

CPS (Streptococcus pneumoniae capsular polysaccharide)

Beyond the preview

Go deeper on LBVE02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LBVE02.